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Received April 23, 2012; accepted September 5, 2012AbstractBackground: Takayasu’s arteritis (TA) is a chronic inflammatory disease that involves the aorta and its major branches; however, only limited
data are available on TA in Taiwan. This study presents the clinical features, angiographic findings, and response to treatment of patients with TA
at a single institute in Taiwan.
Methods: A search of the hospital database for ICD9 code 446.7 (Takayasu’s disease) between 1990 and 2010 was performed. Seven cases
fulfilled the 1990 American College of Rheumatology diagnostic criteria for Takayasu’s disease. Angiographic classification was made
according to the guidelines of the 1994 International TA Conference in Tokyo.
Results: All of our cases were female, and the median age at diagnosis was 27.5 years (range 14e36 years). Four patients had an angiographic
classification of type I (57.1%), two were classified as type V (28.6%), and one was classified as type III (14.3%). The most common symptoms/
signs were dizziness and vascular bruits. Two patients underwent bypass surgery, four endovascular stenting, and one hybrid bypass with
stenting. After a mean follow-up period of 50.3  68.2 months (range 12.3e199.6 months), both the procedure success and survival rates were
100%. There were four restenosis cases (57.1%), one in the surgical bypass group without symptoms (33.3%), and three in the endovascular
group (60%), five restenosis in 14 stents (35.7%). Also, these three patients received secondary endovascular procedure for percutaneous
transluminal angioplasty or restenting.
Conclusion: There have not been any case series reports about treatments of Takayasu’s disease in Taiwan to date, based on a search of the
PubMed/MEDLINE and Cochrane Library databases. Although endovascular treatment is becoming more prevalent, the restenosis rate is still
high, and long-term follow-up and further strategy for restenosis management are the main challenges.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Takayasu’s arteritis (TA) is a chronic inflammatory disease
that primarily affects the aorta and its main branches. TA is
a rare disease, most commonly seen in Japan, Southeast Asia,
India, and Mexico. The annual incidence of TA has been
estimated at 2.6 per million in North America.1 About
100e200 new cases of TA are registered each year in Japan2;* Corresponding author. Dr. Chun-Che Shih, Division of Cardiovascular
Surgery, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road,
Taipei 112, Taiwan, ROC.
E-mail address: ccshih@vghtpe.gov.tw (C.-C. Shih).
1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.10.006so far, more than 5000 cases have been registered in Japan,3
whereas there have only been sporadic case reports in Taiwan.
For the purpose of providing objective data on the clinical
course of TA in Taiwan, we reviewed the clinical symptoms/
signs, angiographic findings, treatments, and outcomes of this
disease at our institute over a 20-year period.
2. Methods
Using ICD9 code 446.7 (Takayasu’s disease), we performed
a search of the hospital database and identified a total of 18 cases
between 1990 and 2010. After a chart review, it was noted that
seven patients fulfilled the American College of Rheumatologyhinese Medical Association. All rights reserved.
Table 1
Patient characteristics.
Case
no.
Gender Age at
diagnosis
Angiographic
characteristic
Primary intervention
1 F 32 Type V Aorto-bil carotid bypass
2 F 36 Type I Aorto-bil carotid bypass þ
R’t C-S bypass þ L’t VA stenting
3 F 28 Type I Carotid stents, twice
4 F 14 Type I Carotid stents
5 F 30 Type III Aorto-bil iliac bypass
6 F 23 Type I Carotid stents, twice
7 F 20 Type V Carotid stent
L’t VA stent ¼ left veterbral artery stenting; R’t C-S bypass ¼ right carotid
subclavian bypass.
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cation was made according to the guidelines established by the
International TA Conference in Tokyo in 1994.5
3. Results3.1. Patient characteristicsSeven cases fulfilled the American College of Rheuma-
tology criteria for TA, all of whom were female with a median
age at diagnosis of 27.5 years (range 14e36 years). Four of
them had an angiographic classification of type I (57.1%), two
were classified as type V (28.6%), and one was classified as
type III (14.3%). The type III patient had received an aorto-
bilateral iliac bypass at another hospital, and had been fol-
lowed up at the Rheumatology department of our institution
for medication. The demographic data of the patients are
shown in Table 1.
The symptoms and signs were reviewed by medical charts.
Constitutional symptoms including fever, headache, dizziness,
and malaise, and vascular findings including vascular bruits,
absence of arm pulse, claudication of the extremities, visual
disturbance, and syncope were noted (Table 2). Dizziness and
vascular bruits (carotid artery) were found in all type I and
type V cases, and an absence of arm pulse was found in five
patients (83.3%).3.2. Treatment modality
3.2.1. Surgical bypass group
Three patients underwent a surgical bypass. One received
an aorto-bilateral carotid bypass in 1994, when a bifurcatedTable 2
Patients’ symptoms and signs.
Fever Absent
arm pulse
Vascular
bruits
Claudication of the
extremities
Headache
1   þ  
2  þ þ þ þ
3  þ þ þ þ
4  þ þ þ 
5 d d d d d
6  þ þ þ 
7  þ þ  þ
d 0 83.30% 100% 66.70% 50%
MCA ¼ middle cerebral artery; RA ¼ rheumatoid arthritis; SLE ¼ systemic lupuDacron graft (20  10 mm) was interposed between the
ascending aorta and bilateral common carotid artery (Fig. 1).
Another patient received an aorto-bilateral carotid bypass in
2006 with separated 7-mm grafts from the aorta to bilateral
common carotid arteries, and then switched one 6-mm graft to
connect from the right carotid graft to the right subclavian
artery. The patient with an angiographic classification of type
III received an aorto-bilateral iliac bypass at another hospital
in 2008. Overall, no complications were recorded.
3.2.2. Endovascular revascularization group
Five patients underwent endovascular interventions, and
stents were implanted in all patients (Table 3, Fig. 2). Three
patients received scheduled second-time interventions because
of multiple-site stenosis. A total of 14 stents were implanted,
and the primary success rate was 100%. Two immediate
procedure-related complications were femoral artery throm-
bosis and femoral artery pseudoaneurysm that occurred at the
vascular puncture site; both required urgent operation for
vascular repair.3.3. RestenosisUp to the end of March 2012, with mean follow-up period
of 50.3  68.2 months (range 12.3e199.6 months) in total and
27.0  22.1 months (range 12.3e64.9 months) in the endo-
vascular group, the procedure success and long-term survival
rates were both 100%. Four patients (57.1%) were still found
to have graft, anastomosis site, and in-stent or stent edge
stenosis. One patient from the surgical group experienced right
aortocarotid bypass restenosis 4.5 years after the operation,
and three patients in the endovascular group experienced
restenosis with five stents (3/5 patients: 60%; 5 in 14 stents:
35.7%). All three patients received secondary intervention for
restenosis, and mean days to secondary intervention were 322
days (Table 3).
One patient suffered from multiple marginal restenosis 6
months after stents insertion at the distal left common carotid
artery and proximal left subclavian artery (LSA); rupture of
subclavian stent at aneurysm site was also found (Fig. 3).
Restenting was performed, but she suffered another episode of
limb claudication after 6 months. Angiogram showed LSA
restenosis; thus, percutaneous transluminal angioplasty (PTA)
was performed.Dizziness Syncope Visual
disturbance
Malaise Others
þ    RA
þ  þ þ d
þ þ þ  d
þ þ   d
d d d d Type III
þ  þ  TIA, MCA infarction
þ  þ þ SLE
100% 33.30% 66.70% 16.7% d
s erythematosus; TIA ¼ transient ischemic attack.
Fig. 1. Representative surgical bypass group with bilateral aortocarotid and carotid-subclavian bypasses.
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stent, experienced in-stent restenosis after 1 year. Restenting
of a drug-eluting stent (DES) was performed.3.4. MedicationSix patients received oral steroids with different initial
doses and durations. One patient who was also diagnosed to
have rheumatoid arthritis took cyclosporine. Five of the seven
patients took antiplatelet agents.
4. Discussion
The average patient age of 27.5 years at diagnosis in our
study is consistent with previous reports from the UnitedTable 3
Treatment modality in the endovascular group.
Received treatment
(first/second
intervention)
Primary intervention Restenosis
Aortocarotid
bypass þ R’t C-S
bypass/L’t VA stent
2006-10-24 /2007-1-25 Right aortocarotid
bypass in 2011-4
Carotid stent
LCCA þ LSA/RCCA
2008-7-2 /2008-8-13 d
Carotid stent
LICA þ LAA
2010-6-30 Distal
LCCA þ proximal
marginal restenosis of
LSA
Carotid stent
RCCA þ RSA/
LCCA þ LSA
2009-12-30/2010-4-30 RCCA and LSA in
2011-3
Carotid stent RCCA 2011-2-10 In-stent restenosis
LCCA ¼ left common carotid artery; LSA ¼ left subclavian artery; L’t VA ¼ left
subclavian artery; R’t C-S bypass ¼ right carotid-subclavian bypass; RCCA ¼ rigStates, Japan, South Korea, and China.6e10 However, none of
the patients was older than 40 years at the time of diagnosis in
our study compared to 9.6% in China, as reported by Cong
et al10 in 125 cases, and 23.1% in South Korea, as reported by
Park et al11 in 108 cases.
All of our patients were female, whereas other studies have
shown varying female/male ratios ranging from 1.2:1 to 9.4:1.
All of our type I and type V TA patients complained about
dizziness and vascular bruits at the time of diagnosis. The
“classic” symptoms of TA, such as an absence of arm pulse,
extremity claudication, and visual disturbance, were present in
most of our cases.12 The predominant anatomic lesions were
stenosis or occlusion, which is similar to the angiographic
features reported in other countries,10,11 albeit that the
involvement of different arteries shows variation by country.Secondary intervention
for restenosis
Days to secondary
intervention (d)
Complications
d d None
d d Femoral artery
thrombosis
LAA-
LSA þ LICA e LCCA
re-stenting on 2011-1-28
212 Rerestenosis over LSA,
PTA on day 201 after
previous procedure
PTA of PCCA and LSA
on 2011-8-31
394 Femoral artery
pseudoaneurysm
RCCA re-stenting on
2012-2-6
361 d
vertebral artery; PTA ¼ percutaneous transluminal angioplasty; RSA ¼ right
ht common carotid artery.
Fig. 2. Representative endovascular stenting group with bilateral carotid and left subclavian artery stents.
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disease pattern, which is similar to that observed in China,
South Korea, and Colombia. In contrast, type V is the most
commonly found pattern in Thailand, Brazil, India, and Japan,
but less commonly found in China and Taiwan (Table 4). The
different distribution of vascular involvement in different
geographical areas might indicate that ethnic factors play an
important role in TA.
Even though there were a limited number of cases in our
study, we still observed a potentially longer patency in the
surgical bypass group. Although the role of endovascularFig. 3. Typical angiographic manifestation of marginal restenosis of left carotid ar
months of follow-up.stenting/PTA in TA has been progressing recently, long-term
follow-up data are still lacking. Tyagi et al13 reported
successful angioplasty over renal arteries in TA in 89.3% of
54 cases (67 of 75 lesions attempted), with restenosis occur-
ring in seven of 52 (13.5%) lesions over a follow-up period of
43.4 months. Sharma et al14 reported 16 stents over different
sites with restenosis in two carotid stents over a short-term
follow-up period of 6 months. Sakaida et al15 placed 14
stents over carotid and subclavian arteries with a 91% success
rate, and only one case of restenosis in 12 months of
follow-up.16tery stent, proximal restenosis and rupture of a subclavian artery stent after 6
Table 4
Angiographic classification type in different countries.
Type TPEVGH China Thailand Korea Brazil Colombia India Japan Iran
I 4 (57.1%) 50 (40%) 0 39 (36.1%) 4 (13.3%) 12 (34.3%) 7 (6.9%) 19 (24.1%) 8 (10.3%)
IIa 0 6 (4.8%) 0 3 (2.8%) 1 (3.3%) 4 (11.4) 1 (1.0%) 9 (11.4%) 12 (15.4%)
IIb 0 2 (1.6%) 7 (11.1%) 5 (4.6%) 0 2 (5.7%) 6 (5.9%) 8 (10.1%) 0
III 1 (14.3%) 3 (2.4%) 2 (3.2%%) 8 (7.4%) 1 (3.3%) 0 3 (2.9%) 0 14 (17.9%)
IV 0 26 (20.8%) 12 (19.0%) 17 (15.7%) 4 (13.3%) 7 (20.0%) 29 (28.4) 1 (1.3%) 14 (17.9%)
V 2 (29.6%) 38 (30.4%) 42 (66.7%) 36 (33.3%) 20 (66.7%) 10 (28.6%) 56 (54.9%) 42 (53.2%) 30 (38.5%)
Total 7 125 63 108 30 35 102 79 78
TPEVGH ¼ Taipei Veterans General Hospital.
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required reintervention. The restenosis period occurred about
1 year later (mean 322 days, range 212e394 days). A recent
study in China also observed that restenosis occurred mostly
in the first year.10 Sharma et al17 had mentioned that the
noncompliant and fibrotic nature vessel wall in TA requires
higher balloon inflation pressure, and this may expose the
vessel wall to increased risk of injury. Stenostic vessels in TA
were often long lesions, and it has been noted that higher rates
of restenosis correlate with the length of lesions in both
atherosclerosis and TA. Better results of PTA in TA were
observed in renal arteries, wherein lesions were short and
focal.13
However, the long-term follow-up of stent patency and the
management of restenosis are the most difficult issues to be
faced in the future. Bypass surgery remains the gold standard
for achieving long-term patency. Endovascular treatment
provides symptoms relief in a shorter period for those who are
reluctant to undergo this operation. Moreover, doctors should
always preserve the anastomosis sites for future bypass
surgery while they are performing endovascular stents
placement.
There have been sporadic cases of DES implantation over
carotid arteries in Takayasu’s disease. The long-term patency
was inconsistent; more studies are necessary to gauge the
effectiveness of DESs in Takayasu’s disease.
Taipei Veterans General Hospital is a tertiary referral
medical center in Taiwan, but even so there have only been
seven confirmed cases of Takayasu’s disease in the past 20
years. In addition, no other case series have been reported in
Taiwan. The realistic epidemiological phenomenon of
Takayasu’s disease in Taiwan needs more interhospital cohort
study.
In conclusion, although the number of cases is limited in
this study, this is the only reported series of Takayasu’s disease
in Taiwan. Most of our cases had an angiographic classifica-
tion of type I. Endovascular treatment for this disease is an
alternative choice with a high initial success rate and low
complication rate; restenosis rates are high and usually occur
in the first year. The management of restenosis for patients
who receive endovascular stents is the main challenge.References
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